Skip to main content

2023 ASCO Annual Meeting Coverage

T-DXd offers ‘clinically meaningful activity’ across HER2-positive tumors

22-06-2023 Trastuzumab Deruxtecan News

Trastuzumab deruxtecan could offer a tumor-agnostic treatment option for patients with HER2-expressing malignancies.

ZUMA-7 update confirms axi-cel OS benefit for large B-cell lymphoma

20-06-2023 Non-Hodgkin Lymphoma News

Autologous anti-CD19 CAR T-cell therapy significantly improves overall survival versus standard care for patients with relapsed or refractory large B-cell lymphoma.

KEYNOTE-671 supports perioperative pembrolizumab for resectable NSCLC

15-06-2023 NSCLC News

The KEYNOTE-671 trial points to a significant improvement in event-free survival for patients with early-stage, non-small-cell lung cancer with use of pembrolizumab before and after surgery.

Vorasidenib boosts PFS in IDH-mutated low-grade glioma

09-06-2023 Glioma News

The INDIGO study has shown a significant progression-free survival benefit of vorasidenib in people with grade 2 glioma with IDH mutations.

FOLFOX response allows rectal cancer patients to forego neoadjuvant radiotherapy

08-06-2023 Rectal Cancer News

Preoperative pelvic radiotherapy can be omitted in patients with locally advanced rectal cancer who respond to neoadjuvant chemotherapy, say the PROSPECT investigators.

Adjuvant ribociclib reduces recurrence risk in early breast cancer

05-06-2023 Breast Cancer News

Supplementing endocrine therapy with ribociclib significantly decreases the relapse risk in people with hormone receptor-positive, HER2-negative, early breast cancer.

Our tailored content service will keep you up to date…

Receive newsletters curated for the busy specialist by our expert editorial team

Stay up to date with more from Springer Medicine

Keynote webinar | Spotlight on cardio-oncology

Webinar | 16-05-2023 | 17:30 (CET)

An expert-led symposium exploring the most pertinent issues in cardio-oncology, with a focus on the new ESC guidelines. Highlights include preventative approaches in cardio-oncology, toxicity risk-stratification strategies, the clinical management of myocarditis as an adverse effect of immune checkpoint inhibitor-treatments, and the utility of biomarkers in long-term follow-up of cardiovascular disease risk in cancer patients.

Prof. Rudolf de Boer
Prof. Lorenz Lehmann
Dr. Teresa Lopéz Fernández
Developed by: Springer Medicine

Episode 2: Progress in PARP inhibitors

In this episode, Dr. Elena Castro takes us through the latest evidence for PARP inhibitors and their combinations in this setting. 

» Listen now


Dr. Elena Castro

Biomarker-driven management of NSCLC (Link opens in a new window)

NSCLC CME Course

Expert-led, multiformat program which will address the individualized management of NSCLC, through education on the detection of NTRK gene fusions, current evidence-based guidelines, and new and emerging therapies. Will also include guidance on integrating shared decision making into your clinical practice, drawing on insights from a patient on how best to communicate.

1.0 AMA PRA Category 1 Credit(s)™

Supported by:
  • Bayer HealthCare Pharmaceuticals Inc.